Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 18/20 | 0.61 |
| ▸ | CYSLTR1 | Q9Y271 | 18/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3095269 | 0.81 | CYSLTR2 (0.61) | CYSLTR2CYSLTR1 | |
| SCHEMBL3099336 | 0.80 | CYSLTR2 (0.77) | CYSLTR2CYSLTR1 | |
| SCHEMBL3090758 | 0.79 | CYSLTR2 (0.79) | CYSLTR2CYSLTR1 | |
| SCHEMBL3102893 | 0.79 | CYSLTR2 (0.68) | CYSLTR2CYSLTR1 | |
| SCHEMBL3099409 | 0.76 | CYSLTR2 (1.00) | CYSLTR2CYSLTR1 | |
| SCHEMBL3099238 | 0.76 | CYSLTR2 (0.89) | CYSLTR2CYSLTR1 | |
| SCHEMBL3099183 | 0.75 | CYSLTR2 (0.65) | CYSLTR2CYSLTR1 | |
| SCHEMBL3105457 | 0.74 | CYSLTR2 (0.76) | CYSLTR2CYSLTR1 | |
| SCHEMBL3102804 | 0.74 | CYSLTR2 (0.89) | CYSLTR2CYSLTR1 | |
| SCHEMBL3087902 | 0.74 | CYSLTR2 (0.65) | CYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318952-B2 | Substituted indole derivatives for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| EP-2481732-A1 | Condensed ring compound and use thereof | Ono Pharmaceutical Co., Ltd. (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | TAKEUCHI JUN | 2010-09-16 | — | — | US | disclosed |
| US-7763610-B2 | Carboxylic acid derived benzoxazines as agents for the treatment of respiratory diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20060194797-A1 | Condensed ring compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-31 | — | — | US | disclosed |
| EP-1661892-A1 | CONDENSED RING COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234368-A1 | CONDENSED RING COMPOUND AND USE THEREOF | CYSLTR2, CYSLTR1, LTB4R2 | CYSLTR2 1/4885CYSLTR1 2/4885LMNA 4286/4885 |
| US-20060194797-A1 | Condensed ring compound and use thereof | CYSLTR2, CYSLTR1, LTB4R2 | CYSLTR2 1/4885CYSLTR1 2/4885LMNA 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.